24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825
Fax: (361)578-5500

Medical Disorders
Resources
Basic InformationLookupsLatest News
Health Tip: Recognizing a Staph InfectionIs Dairy Fat Different?CDC Recommends Catch-Up HPV Vaccination for Young AdultsHow to Relieve Dry, Irritated EyesPretomanid Approved for Treatment of Drug-Resistant TBAHA News: Tiring Easily May Warn of Future Heart TroubleAmerica's Obesity Epidemic May Mean Some Cancers Are Striking SoonerHeavy Smog as Bad as Pack-a-Day Smoking for LungsConcussed NFL Players Sidelined for Much Longer NowadaysHormone Therapy for Prostate Cancer Might Harm the Heart: StudyObesity and 'Spare Tire' Raise Hispanics' Odds for Early DeathAHA News: Protein Made During Long Workouts May Warn of Heart ProblemsHow to Help Your Heart Weather Extreme HeatHealth Threats Don't End for Some Sepsis SurvivorsHeat Waves Brought by Climate Change Could Prove Deadly for Kidney PatientsHealth Tip: Avoiding AnemiaAre You Still Putting Off Colon Cancer Screening?Tips for Preventing DiverticulitisFDA Reports More Seizures Among VapersKids Getting Too Many Opioids After TonsillectomyCan Major Surgeries Cause a Long-Term 'Brain Drain'?How Much Coffee Is Too Much for Migraine Sufferers?Steady Stream of Lesser Head Hits in Football Can Still Damage BrainDon't Sweat It: Hyperhydrosis Can Be TreatedFast-Food Joints on Your Way to Work? Your Waistline May WidenAdults Need Vaccines, TooHealth Tip: Managing Arthritis of the Hands'Selfies' Might Someday Track Your Blood PressureIn Heat Waves, Fans May Do More Harm Than GoodSmoking Creates Long-Lasting Risk for Clogged Leg ArteriesFootball Head Trauma Linked Again to Long-Term Brain DamageDrug Approved to Treat Tenosynovial Giant Cell TumorRugby-Style Tackling Might Make Football SaferFor Kids With Asthma, Allergies, New School Year Can Bring Flare-UpsFrailty Not a Normal Part of AgingAHA News: Hurricane Checklist: Batteries, Bottled Water – And A Plan for Heart CareDangerous Sesame Allergy Affects Many AmericansScorching Pavement Sends Some to the ER With BurnsHealth Tip: Living With Hypoglycemia3-D Printers Might Someday Make Replacement HeartsCDC Renews Pledge to Fight Ebola Outbreak in AfricaAnemia Linked to Higher Odds for Dementia in SeniorsDrug Duo May Be an Advance Against a Common LeukemiaAHA News: Chemical Widely Used in Medical Plastic Alters Heart Function in Lab TestsHigh Blood Pressure Much More Deadly for the PoorHealth Tip: Understanding PrediabetesMild Head Injury Can Impair Your Sense of SmellMiddle Age Now a High-Risk Time for Bad FallsSmoking May Interfere With 'Embolization' Lung TreatmentHeartburn Drugs Might Bring Allergy Woes
Questions and AnswersLinks
Related Topics

Diabetes

FDA Approves First Gene Therapy for Spinal Muscular Atrophy


HealthDay News
Updated: May 28th 2019

new article illustration

TUESDAY, May 28, 2019 (HealthDay News) -- The first gene therapy has been approved to treat children younger than 2 years with spinal muscular atrophy (SMA), the U.S. Food and Drug Administration announced Friday.

Zolgensma (onasemnogene abeparvovec-xioi), an adeno-associated virus vector-based gene therapy, targets the cause of SMA by delivering a fully functional copy of the human SMN1 gene into the target motor neuron cells. According to the FDA, a one-time intravenous administration of the drug yields expression of the SMN protein in a child's motor neurons, which improves movement, function, and survival. Dosing is based on patient weight, with a recommended dosage of 1.1 × 1.014 vector genomes per kilogram of body weight. Zolgensma is administered as an intravenous infusion for 60 minutes.

Approval was based on two clinical trials, one ongoing. The completed clinical trial involved 36 children with infantile-onset SMA who were 2 weeks to 8 months old at study initiation. In the ongoing clinical trial, which initially included 21 patients, the 19 remaining patients are 9.4 to 18.5 months old. These patients have demonstrated significant improvement in reaching developmental motor milestones compared with the natural history of patients with infantile-onset SMA.

Commonly reported side effects include elevated liver enzymes and vomiting. A boxed warning included with the prescribing information indicates the risk for acute serious liver injury and warns that patients with preexisting liver impairment may be at higher risk. Before initiating treatment with Zolgensma and for at least three months after administration, clinicians should assess patients' liver function through clinical examination and laboratory testing. Patients should also be administered an oral corticosteroid before and after Zolgensma infusion; because certain vaccines are contraindicated for patients taking a corticosteroid, caregivers should consult with clinicians to determine if adjustments to the child's immunization schedule are necessary.

Approval of Zolgensma was granted to AveXis.

More Information